Loading...
•
Mar 31, 2023
Organon Q1 2023 Earnings Report
Organon's Q1 2023 results were announced, showcasing constant currency product sales growth and strategic capital allocation.
Key Takeaways
Organon reported a 2% decrease in total revenue as-reported, but a 3% increase excluding the impact of foreign currency, reaching $1,538 million. The company experienced growth in Women's Health and Biosimilars revenues, while Established Brands showed resilience. Net income was $177 million, or $0.69 per diluted share, and non-GAAP adjusted net income was $276 million, or $1.08 per diluted share.
Total revenue was $1,538 million, a decrease of 2% as-reported but an increase of 3% ex-FX.
Women’s Health revenue grew 1% as-reported and 3% ex-FX.
Biosimilars revenue increased 18% as-reported and 20% ex-FX.
Established Brands revenue decreased 5% as-reported but increased 1% ex-FX.
Forward Guidance
Organon's full year 2023 financial guidance is presented on a non-GAAP basis.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...